Managing Relapsed/Refractory Multiple Myeloma:
Pharmacist Focus on the Expanding Treatment Landscape

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Pfizer..

Registration & Dates for Activities

Thursday, December 14, 2023
3:00-4:00 PM ET
Tuesday, December 19, 2023
2:00-3:00 PM ET


Anthony J. Perissinotti, PharmD, BCOP
Clinical Pharmacist Specialist, Inpatient Hematology
Clinical Team Lead - Hematology/Oncology
University of Michigan - Michigan Medicine
Ann Arbor, Michigan


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-23-110-L01-P
Credits: 1.0 hour (0.1 ceu)
Estimated time to complete activity: 60-minutes

Location: From the convenience of your home or business; accessible via both PC and MAC
Fee Information:
There is no fee. This is a free continuing education activity.
Type of Activity:
Media: Internet


This accredited activity has been designed for oncology, managed care and specialty pharmacists.


Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.


The goal of this educational activity is to provide oncology, managed care, and specialty pharmacists with advanced and up-to-date knowledge of the evolving relapsed or refractory multiple myeloma (R/R MM) treatment landscape, to ensure appropriate access to patient-specific treatments, optimal toxicity prevention and management, and enhanced pharmaceutical care, thus leading to improved outcomes.


At the conclusion of this program, the learner will be able to do the following:

  • Describe the mechanism of action for current and emerging treatments for relapsed or refractory multiple myeloma (R/R MM)
  • Evaluate the efficacy and safety of current and emerging treatments for R/R MM for individualized treatment selection
  • Formulate effective strategies to improve patient outcomes with supportive care for patients receiving treatment for R/R MM


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Pfizer. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.

There are no available webinars at this time.